Results 11 to 20 of about 115,290 (264)

Direct oral anticoagulant interference and removal in the factor VIII inhibitor assay [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Direct oral anticoagulants (DOACs) interfere with clot-based assays, including factor (F)VIII testing and the Nijmegen–Bethesda assay, potentially leading to false-positive results for FVIII inhibitors.
Rick Timmerije, Saskia E.M. Schols, Daniëlle Meijer, Wideke Barteling, An K. Stroobants, Sanna R. Rijpma   +5 more
doaj   +2 more sources

Deleterious variants cluster in the A3 domain of factor VIII in people with severe hemophilia A and inhibitors [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Hemophilia A (HA) is an X-linked disorder due to deleterious variants in the factor VIII (FVIII) gene (F8). Few studies from large cohorts have explored F8 genotype in people with HA with origins other than North American and European ...
Luciana Werneck Zuccherato, Renan Pedra Souza, Ricardo Mesquita Camelo, Márcio Antônio Portugal Santana, Maíse Moreira Dias, Letícia Lemos Jardim, Andrea Gonçalves de Oliveira, Claudia Santos Lorenzato, Monica Hermida Cerqueira, Vivian Karla Brognoli Franco, Rosangela de Albuquerque Ribeiro, Leina Yukari Etto, Maria do Rosario Ferraz Roberti, Fábia Michelle Rodrigues de Araújo Callado, Maria Aline Ferreira de Cerqueira, Ieda Solange de Souza Pinto, Andrea Aparecida Garcia, Tania Hissa Anegawa, Daniele Campos Fontes Neves, Daniel Gonçalves Chaves, Suely Meireles Rezende   +20 more
doaj   +2 more sources

Acquired Factor VIII Deficiency Presenting as Gross Hematuria in a Hispanic, Pregnant Patient with Previously Undiagnosed Connective Tissue Disease

Case Reports in Rheumatology, 2021
Acquired factor VIII deficiency is a bleeding disorder caused by the presence of autoantibodies against clotting factor VIII. We report a case of a 24-year-old pregnant woman who presented with gross hematuria secondary to acquired factor VIII deficiency
Christine Loftis, Emilia C. Dulgheru, Rosa White   +2 more
doaj   +1 more source

Calcium Prevents Enhanced Degradation of Factor VIII in the Condition of Motion

Biology, 2023
Background: Hemophilia A and B induce recurrent bleeding episodes, mainly in skeletal muscles and joints that are in intermittent motion. We have previously demonstrated that intermittent motion contributes to increased degradation of factors VIII and IX.
Haim Cohen, Anat Keren-Politansky, Yonatan Crispel, Chen Yanovich, Keren Asayag, Yona Nadir   +5 more
doaj   +1 more source

Identification of Key Coagulation Activity Determining Elements in Canine Factor VIII

Molecular Therapy: Methods & Clinical Development, 2020
It is well known that canine factor VIII (cFVIII) has a higher specific activity than does human FVIII (hFVIII), and it has been previously demonstrated that cFVIII light chain is able to enhance hFVIII activity.
Jenni Firrman, Qizhao Wang, Wenman Wu, Biao Dong, Wenjing Cao, Andrea Rossi Moore, Sean Roberts, Barbara A. Konkle, Carol Miao, LinShu Liu, Dong Li, Weidong Xiao   +11 more
doaj   +1 more source

Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021

Research and Practice in Thrombosis and Haemostasis, 2021
The most serious complication of factor VIII (FVIII) replacement therapy is the occurrence of anti‐FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII products.
Yesim Dargaud, Carmen Escuriola‐Ettingshausen   +1 more
doaj   +1 more source

Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?

Haematologica, 2019
Therapeutic factor VIII is highly immunogenic. Despite intensive research in the last decades, the reasons why 5-30% of patients with hemophilia A (of all severities) develop inhibitory anti-factor VIII antibodies (inhibitors) following replacement ...
Aditi Varthaman, Sébastien Lacroix-Desmazes   +1 more
doaj   +1 more source

Extrahepatic sources of factor VIII potentially contribute to the coagulation cascade correcting the bleeding phenotype of mice with hemophilia A

Haematologica, 2015
A large fraction of factor VIII in blood originates from liver sinusoidal endothelial cells although extrahepatic sources also contribute to plasma factor VIII levels.
Diego Zanolini, Simone Merlin, Maria Feola, Gabriella Ranaldo, Angela Amoruso, Gianluca Gaidano, Mauro Zaffaroni, Alessandro Ferrero, Sandra Brunelleschi, Guido Valente, Sanjeev Gupta, Maria Prat, Antonia Follenzi   +12 more
doaj   +1 more source

Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients

Haematologica, 2013
Since 1981, the number of factor VIII units to infuse into patients with hemophilia A in order to achieve adequate circulating factor VIII levels has been calculated using the formula: [body weight(kg)×desired factor VIII increase(%)]/2, assuming a ...
Séverine Henrard, Niko Speybroeck, Cedric Hermans   +2 more
doaj   +1 more source

Modelling US health equity impacts of emicizumab for severe haemophilia A: aggregate distributional cost-effectiveness analysis

BMJ Open
Objectives Emicizumab is the first bispecific antibody approved for prophylaxis in people with haemophilia A with or without factor VIII inhibitors. Aggregate distributional cost-effectiveness analysis assesses health equity impacts by evaluating how ...
Randall Curtis, Thomas Majda, Janet S. Lee, Stacey L. Kowal   +3 more
doaj   +1 more source